Drugs and liver injury: a not to be overlooked binomial in COVID-19

References

• WHO Coronavirus Disease (COVID-19) Dashboard. Available from: https://covid19.who.int/. [last updated 2021 Mar 14]
   Google Scholar
• Lotfi M, Rezaei N. SARS-CoV-2: a comprehensive review from pathogenicity of the virus to clinical consequences. J Med Virol. 2020;92(10):1864–1874.
   PubMedGoogle Scholar
• Syed A, Khan A, Gosai F, et al. Gastrointestinal pathophysiology of SARS-CoV2 - a literature review. J Community Hosp Intern Med Perspect. 2020;10(6):523–528.
   PubMed Web of Science ®Google Scholar
• Jothimani D, Venugopal R, Abedin MF, et al. COVID-19 and the liver. J Hepatol. 2020;73(5):1231–1240.
   PubMed Web of Science ®Google Scholar
• Wang JT, Sheng WH, Fang CT, et al. Clinical manifestations, laboratory findings, and treatment outcomes of SARS patients. Emerg Infect Dis. 2004;10(5):818–824.
   PubMed Web of Science ®Google Scholar
• Alqahtani SA, Schattenberg JM. Liver injury in COVID-19: the current evidence. United Eur Gastroenterol J. 2020;8(5):509–519.
   PubMed Web of Science ®Google Scholar
• Bertolini A, van de Peppel IP, Bodewes FAJA, et al. Abnormal liver function tests in patients with COVID-19: relevance and potential pathogenesis. Hepatology. 2020;72(5):1864–1872.
   PubMed Web of Science ®Google Scholar
• Li J, Fan JG. Characteristics and mechanism of liver injury in 2019 coronavirus disease. J Clin Transl Hepatol. 2020;8(1):13–17.
   PubMed Web of Science ®Google Scholar
• Cai Q, Huang D, Yu H, et al. COVID-19: Abnormal liver function tests. J Hepatol. 2020;73(3):566–574.
   PubMed Web of Science ®Google Scholar
• Lei F, Liu YM, Zhou F, et al. Longitudinal association between markers of liver injury and mortality in COVID-19 in China. Hepatology. 2020;72(2):389–398.
   PubMed Web of Science ®Google Scholar
• Galiero R, Pafundi PC, Simeon V, et al. Impact of chronic liver disease upon admission on COVID-19 in-hospital mortality: findings from COVOCA study. PLoS One. 2020;15(12):e0243700.
   PubMedGoogle Scholar
• Iavarone M, D'Ambrosio R, Soria A, et al. High rates of 30-day mortality in patients with cirrhosis and COVID-19. J Hepatol. 2020;73(5):1063–1071.
   PubMed Web of Science ®Google Scholar
• Sarin SK, Choudhury A, Lau GK, et al. Pre-existing liver disease is associated with poor outcome in patients with SARS CoV2 infection; the APCOLIS study (APASL COVID-19 liver injury spectrum study). Hepatol Int. 2020;14(5):690–700.
   PubMedGoogle Scholar
• Zhao JN, Fan Y, Wu SD. Liver injury in COVID-19: a minireview. World J Clin Cases. 2020;8(19):4303–4310.
   PubMedGoogle Scholar
• Zhong P, Xu J, Yang D, et al. COVID 19-associated gastrointestinal and liver injury: clinical features and potential mechanisms. Signal Transduct Target Ther. 2020;5(1):256.
   PubMedGoogle Scholar
• Zhang C, Shi L, Wang FS. Liver injury in COVID-19: management and challenges. Lancet Gastroenterol Hepatol. 2020 May;5(5):428–430.
   PubMed Web of Science ®Google Scholar
• Zhao D, Yao F, Wang L, et al. A comparative study on the clinical features of coronavirus 2019 (COVID-19) pneumonia with other pneumonias. Clin Infect Dis. 2020;71(15):756–761.
   PubMed Web of Science ®Google Scholar
• Yao N, Wang SN, Lian JQ, et al. Clinical characteristics and influencing factors of patients with novel coronavirus pneumonia combined with liver injury in Shaanxi region. Zhonghua Gan Zang Bing Za Zhi. 2020;28(3):234–239.
   PubMedGoogle Scholar
• Hamid S, Alvares da Silva MR, Burak KW, et al. WGO guidance for the care of patients with COVID-19 and liver disease. J Clin Gastroenterol. 2021;55(1):1–11.
   PubMedGoogle Scholar
• Hanafy AS, Abd-Elsalam S. Challenges in COVID-19 drug treatment in patients with advanced liver diseases: a hepatology perspective. World J Gastroenterol. 2020;26(46):7272–7286.
   PubMedGoogle Scholar
• Ferron PJ, Gicquel T, Mégarbane B, et al. Treatments in covid-19 patients with pre-existing metabolic dysfunction-associated fatty liver disease: a potential threat for drug-induced liver injury? Biochimie. 2020;179:266–274.
   PubMedGoogle Scholar
• Chu CM, Cheng VCC, Hung IFN, et al. Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings. Thorax. 2004;59(3):252–256.
   PubMed Web of Science ®Google Scholar
• Chan JFW, Yao Y, Yeung ML, et al. Treatment with lopinavir/ritonavir or interferon-β1b improves outcome of MERS-CoV infection in a nonhuman primate model of common marmoset. J Infect Dis. 2015;212(12):1904–1913.
   PubMed Web of Science ®Google Scholar
• Sulkowski MS, Mehta SH, Chaisson RE, et al. Hepatotoxicity associated with protease inhibitor-based antiretroviral regimens with or without concurrent ritonavir. AIDS. 2004;18(17):2277–2284.
   PubMed Web of Science ®Google Scholar
• Cai Q, Huang D, Ou P, et al. COVID-19 in a designated infectious diseases hospital outside Hubei province, China. Allergy. 2020;75(7):1742–1752.
   PubMed Web of Science ®Google Scholar
• Fan Z, Chen L, Li J, et al. Clinical features of COVID-19-Related liver functional abnormality. Clin Gastroenterol Hepatol. 2020;18(7):1561–1566.
   PubMed Web of Science ®Google Scholar
• Zhan K, Liao S, Li J, et al. Risk factors in patients with COVID-19 developing severe liver injury during hospitalisation. Gut. 2021;70(3):628–629.
   PubMedGoogle Scholar
• Levy C, Lassailly G, Parmentier E, et al. Caution with the use of lopinavir/ritonavir in severely ill patients for the treatment of SARS-CoV-2: a report of severe jaundice. Am J Gastroenterol. 2020;115(10):1716–1718.
   PubMed Web of Science ®Google Scholar
• Cao B, Wang Y, Wen D, et al. A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19. N Engl J Med. 2020;382(19):1787–1799.
   PubMed Web of Science ®Google Scholar
• Yip TC, Lui GC, Wong VW, et al. Liver injury is independently associated with adverse clinical outcomes in patients with COVID-19. Gut. 2021;70(4):733–742.
   PubMed Web of Science ®Google Scholar
• Capetti A, Cossu MV, Rizzardini G. Darunavir/cobicistat for the treatment of HIV-1: a new era for compact drugs with high genetic barrier to resistance. Expert Opin Pharmacother. 2015;16(17):2689–2702.
   PubMed Web of Science ®Google Scholar
• Putcharoen O, Do T, Avihingsanon A, et al. Rationale and clinical utility of the darunavir-cobicistat combination in the treatment of HIV/AIDS. Drug Des Devel Ther. 2015;9:5763–5769.
   PubMed Web of Science ®Google Scholar
• Orkin C, DeJesus E, Khanlou H, et al. Final 192-week efficacy and safety of once-daily darunavir/ritonavir compared with lopinavir/ritonavir in HIV-1-infected treatment-naïve patients in the ARTEMIS trial. HIV Med. 2013;14(1):49–59.
   PubMed Web of Science ®Google Scholar
• Singh TU, Parida S, Lingaraju MC, et al. Drug repurposing approach to fight COVID-19. Pharmacol Rep. 2020;72(6):1479–1508.
   PubMed Web of Science ®Google Scholar
• Chen J, Xia L, Liu L, et al. Antiviral activity and safety of darunavir/cobicistat for the treatment of COVID-19. Open Forum Infect Dis. 2020;7(7):ofaa241.
   PubMed Web of Science ®Google Scholar
• Nicolini LA, Mikulska M, Signori A, et al. Reply to: "antiviral activity and safety of darunavir/cobicistat for treatment of COVID-19”. Open Forum Infect Dis. 2020;7(8):ofaa321.
   PubMed Web of Science ®Google Scholar
• Warren TK, Jordan R, Lo MK, Ray AS, et al. Therapeutic efficacy of the small molecule GS-5734 against ebola virus in rhesus monkeys. Nature. 2016;531(7594):381–385.
   PubMed Web of Science ®Google Scholar
• Lo MK, Jordan R, Arvey A, et al. GS-5734 and its parent nucleoside analog inhibit filo-, pneumo-, and paramyxoviruses. Sci Rep. 2017;7:43395.
   PubMed Web of Science ®Google Scholar
• Holshue ML, DeBolt C, Lindquist S, et al. First case of 2019 novel coronavirus in the United States. N Engl J Med. 2020;382(10):929–936.
   PubMed Web of Science ®Google Scholar
• Beigel JH, Tomashek KM, Dodd LE, et al. ACTT-1 study group members. Remdesivir for the treatment of covid-19 - final report. N Engl J Med. 2020;383(19):1813–1826.
   PubMed Web of Science ®Google Scholar
• Montastruc F, Thuriot S, Durrieu G. Hepatic disorders with the use of remdesivir for coronavirus 2019. Clin Gastroenterol Hepatol. 2020;18(12):2835–2836.
   PubMed Web of Science ®Google Scholar
• Goldman JD, Lye DCB, Hui DS, et al. Remdesivir for 5 or 10 days in patients with severe covid-19. N Engl J Med. 2020;383(19):1827–1837.
   PubMed Web of Science ®Google Scholar
• Zampino R, Mele F, Florio LL, et al. Liver injury in remdesivir-treated COVID-19 patients. Hepatol Int. 2020;14(5):881–883.
   PubMed Web of Science ®Google Scholar
• Chen HL, Chao CM, Lai CC. The safety of remdesivir for COVID-19 patients. J Med Virol. 2021;93(4):1910–1912.
   PubMedGoogle Scholar
• Wang Y, Zhang D, Du G, et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet. 2020;395(10236):1569–1578.
   PubMed Web of Science ®Google Scholar
• Spinner CD, Gottlieb RL, Criner GJ, et al. Effect of remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID-19: a randomized clinical trial. JAMA. 2020;324(11):1048–1057.
   PubMed Web of Science ®Google Scholar
• Dong L, Hu S, Gao J. Discovering drugs to treat coronavirus disease 2019 (COVID-19). Drug Discov Ther. 2020;14(1):58–60.
   PubMed Web of Science ®Google Scholar
• Nagata T, Lefor AK, Hasegawa M, et al. Favipiravir: a new medication for the ebola virus disease pandemic. Disaster Med Public Health Prep. 2015;9(1):79–81.
   PubMed Web of Science ®Google Scholar
• Pilkington V, Pepperrell T, Hill A. A review of the safety of favipiravir - a potential treatment in the COVID-19 pandemic? J Virus Erad. 2020;6(2):45–51.
   PubMed Web of Science ®Google Scholar
• Cai Q, Yang M, Liu D, et al. Experimental treatment with favipiravir for COVID-19: an Open-Label control study. Engineering (Beijing). 2020;6(10):1192–1198.
   PubMedGoogle Scholar
• Yan Y, Zou Z, Sun Y, et al. Anti-malaria drug chloroquine is highly effective in treating avian influenza a H5N1 virus infection in an animal model. Cell Res. 2013;23(2):300–302.
   PubMed Web of Science ®Google Scholar
• Jean SS, Lee PI, Hsueh PR. Treatment options for COVID-19: the reality and challenges. J Microbiol Immunol Infect. 2020;53(3):436–443.
   PubMedGoogle Scholar
• Sarma P, Kaur H, Kumar H, et al. Virological and clinical cure in COVID-19 patients treated with hydroxychloroquine: a systematic review and Meta-analysis. J Med Virol. 2020;92(7):776–785.
   PubMed Web of Science ®Google Scholar
• Chen J, Liu D, Liu L, et al. A pilot study of hydroxychloroquine in treatment of patients with moderate COVID‐19. Zhejiang Da Xue Xue Bao Yi Xue Ban. 2020;49(2):215–219.
   PubMedGoogle Scholar
• Das S, Bhowmick S, Tiwari S, et al. An updated systematic review of the therapeutic role of hydroxychloroquine in coronavirus disease-19 (COVID-19). Clin Drug Investig. 2020;40(7):591–601.
   PubMed Web of Science ®Google Scholar
• Cavalcanti AB, Zampieri FG, Rosa RG, et al. Hydroxychloroquine with or without azithromycin in mild-to-Moderate covid-19. N Engl J Med. 2020;383(21):2041–2052.
   PubMed Web of Science ®Google Scholar
• Ye Q, Wang B, Mao J. The pathogenesis and treatment of the `cytokine storm' in COVID-19. J Infect. 2020;80(6):607–613.
   PubMed Web of Science ®Google Scholar
• LiverTox: clinical and research information on drug-Induced liver injury. [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases;2012. Tocilizumab. [Last Update 2020 Apr 18]. https://pubmed.ncbi.nlm.nih.gov/31643176/
   Google Scholar
• Gatti M, Fusaroli M, Caraceni P, et al. Serious adverse events with tocilizumab: pharmacovigilance as an aid to prioritize monitoring in COVID-19. Br J Clin Pharmacol. 2021;87(3):1533–1540.
   PubMed Web of Science ®Google Scholar
• Di Giambenedetto S, Ciccullo A, Borghetti A, et al. Off-label use of tocilizumab in patients with SARS-CoV-2 infection. J Med Virol. 2020;92(10):1787–1788.
   PubMedGoogle Scholar
• Mazzitelli M, Arrighi E, Serapide F, et al. Use of subcutaneous tocilizumab in patients with COVID-19 pneumonia. J Med Virol. 2021;93(1):32–34.
   PubMed Web of Science ®Google Scholar
• Campochiaro C, Della-Torre E, Cavalli G, et al. Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-Centre retrospective cohort study. Eur J Intern Med. 2020;76:43–49. ;.
   PubMed Web of Science ®Google Scholar
• Issa N, Dumery M, Guisset O, et al. Feasibility of tocilizumab in ICU patients with COVID-19. J Med Virol. 2021;93(1):46–47.
   PubMedGoogle Scholar
• Muhović D, Bojović J, Bulatović A, et al. First case of drug-induced liver injury associated with the use of tocilizumab in a patient with COVID-19. Liver Int. 2020;40(8):1901–1905.
   PubMed Web of Science ®Google Scholar
• Serviddio G, Villani R, Stallone G, et al. Tocilizumab and liver injury in patients with COVID-19. Therap Adv Gastroenterol. 2020;13:1756284820959183.
   Google Scholar
• Khiali S, Rezagholizadeh A, Entezari-Maleki T. A comprehensive review on sarilumab in COVID-19. Expert Opin Biol Ther. 2021;21(5):615–626.
   PubMed Web of Science ®Google Scholar
• Della-Torre E, Campochiaro C, Cavalli G, et al. SARI-RAF study group; SARI-RAF study group members. Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation: an open-label cohort study. Ann Rheum Dis. 2020;79(10):1277–1285.
   PubMed Web of Science ®Google Scholar
• Gremese E, Cingolani A, Bosello SL, et al. Sarilumab use in severe SARS-CoV-2 pneumonia. EClinicalMedicine. 2020;27:100553.
   PubMedGoogle Scholar
• Montesarchio V, Parrela R, Iommelli C, et al. Outcomes and biomarker analyses among patients with COVID-19 treated with interleukin 6 (IL-6) receptor antagonist sarilumab at a single institution in Italy. J Immunother Cancer. 2020;8(2):e001089.
   PubMedGoogle Scholar
• van Rhee F, Wong RS, Munshi N, et al. Siltuximab for multicentric castleman's disease: a randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2014;15(9):966–974.
   PubMed Web of Science ®Google Scholar
• Gritti G, Raimondi F, Ripamonti D, et al. IL-6 signalling pathway inactivation with siltuximab in patients with COVID-19 respiratory failure: an observational cohort study. medRxiv Preprint. Available from: https://doi.org/https://doi.org/10.1101/2020.04.01.20048561
   Google Scholar
• Chen X, Liao B, Cheng L, et al. The microbial coinfection in COVID-19. Appl Microbiol Biotechnol. 2020;104(18):7777–7785.
   PubMed Web of Science ®Google Scholar
• Rawson TM, Moore LSP, Zhu N, et al. Bacterial and fungal coinfection in individuals with coronavirus: a rapid review to support COVID-19 antimicrobial prescribing. Clin Infect Dis. 2020;71(9):2459–2468.
   PubMed Web of Science ®Google Scholar
• Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382(18):1708–1720. ;.
   PubMed Web of Science ®Google Scholar
• Lai CC, Shih TP, Ko WC, et al. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): the epidemic and the challenges. Int J Antimicrob Agents. 2020;55(3):105924.
   PubMed Web of Science ®Google Scholar
• Beović B, Doušak M, Ferreira-Coimbra J, et al. Antibiotic use in patients with COVID-19: a 'snapshot' infectious diseases international research initiative (ID-IRI) survey. J Antimicrob Chemother. 2020;75(11):3386–3390.
   PubMed Web of Science ®Google Scholar
• Wang J, Tang Y, Ma Y, et al. Efficacy and safety of antibiotic agents in children with COVID-19: a rapid review. Ann Transl Med. 2020;8(10):619.
   PubMedGoogle Scholar
• Aslam B, Wang W, Arshad MI, et al. Antibiotic resistance: a rundown of a global crisis. Infect Drug Resist. 2018;11:1645–1658.
   PubMed Web of Science ®Google Scholar
• Björnsson ES, Hoofnagle JH. Categorization of drugs implicated in causing liver injury: Critical assessment based on published case reports. Hepatology. 2016;63(2):590–603.
   PubMed Web of Science ®Google Scholar
• Björnsson E, Kalaitzakis E, Olsson R. The impact of eosinophilia and hepatic necrosis on prognosis in patients with drug-induced liver injury. Aliment Pharmacol Ther. 2007;25(12):1411–1421.
   PubMedGoogle Scholar
• Tran DH, Sugamata R, Hirose T, et al. Azithromycin, a 15-membered macrolide antibiotic, inhibits influenza A(H1N1)pdm09 virus infection by interfering with virus internalization process. J Antibiot (Tokyo)). 2019;72(10):759–768.
   PubMed Web of Science ®Google Scholar
• Beigelman A, Isaacson-Schmid M, Sajol G, et al. Randomized trial to evaluate azithromycin's effects on serum and upper airway IL-8 levels and recurrent wheezing in infants with respiratory syncytial virus bronchiolitis. J Allergy Clin Immunol. 2015;135(5):1171–1178.e1.
   PubMed Web of Science ®Google Scholar
• Bleyzac N, Goutelle S, Bourguignon L, et al. Azithromycin for COVID-19: More than just an antimicrobial? Clin Drug Investig. 2020;40(8):683–686.
   PubMed Web of Science ®Google Scholar
• Damle B, Vourvahis M, Wang E, et al. Clinical pharmacology perspectives on the antiviral activity of azithromycin and use in COVID-19. Clin Pharmacol Ther. 2020;108(2):201–211.
   PubMed Web of Science ®Google Scholar
• LiverTox: Clinical and research information on Drug-Induced liver injury. [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases;2012. Macrolide Antibiotics. [Last Update 2017 Aug 10]. https://pubmed.ncbi.nlm.nih.gov/31643176/
   Google Scholar
• Martinez MA, Vuppalanchi R, Fontana RJ, et al. Clinical and histologic features of azithromycin-induced liver injury . Clin Gastroenterol Hepatol. 2015;13(2):369–376.e3.
   PubMedGoogle Scholar
• Olry A, Meunier L, Délire B, et al. Drug-Induced liver injury and COVID-19 infection: the rules remain the same. Drug Saf. 2020;43(7):615–617.
   PubMed Web of Science ®Google Scholar
• Juurlink DN. Safety considerations with chloroquine, hydroxychloroquine and azithromycin in the management of SARS-CoV-2 infection. CMAJ. 2020;192(17):E450–E453.
   PubMed Web of Science ®Google Scholar
• Sodhi M, Etminan M. Therapeutic potential for tetracyclines in the treatment of COVID-19. Pharmacotherapy. 2020;40(5):487–488.
   PubMed Web of Science ®Google Scholar
• Björnsson E, Lindberg J, Olsson R. Liver reactions to oral low-dose tetracyclines. Scand J Gastroenterol. 1997;32(4):390–395.
   PubMed Web of Science ®Google Scholar
• Heaton PC, Fenwick SR, Brewer DE. Association between tetracycline or doxycycline and hepatotoxicity: a population based case-control study. J Clin Pharm Ther. 2007;32(5):483–487.
   PubMed Web of Science ®Google Scholar
• Yates PA, Newman SA, Oshry LJ, et al. Doxycycline treatment of high-risk COVID-19-positive patients with comorbid pulmonary disease. Ther Adv Respir Dis. 2020;14:1753466620951053.
   Web of Science ®Google Scholar
• Vardakas KZ, Kalimeris GD, Triarides NA, et al. An update on adverse drug reactions related to β-lactam antibiotics. Expert Opin Drug Saf. 2018;17(5):499–508.
   PubMed Web of Science ®Google Scholar
• Björnsson ES. Drug-induced liver injury due to antibiotics. Scand J Gastroenterol. 2017;52(6–7):617–623.
   PubMed Web of Science ®Google Scholar
• Smith LA, Ignacio JRA, Winesett MP, et al. Vanishing bile duct syndrome: amoxicillin-clavulanic acid associated intra-hepatic cholestasis responsive to ursodeoxycholic acid. J Pediatr Gastroenterol Nutr. 2005;41(4):469–473.
   PubMed Web of Science ®Google Scholar
• deLemos AS, Ghabril M, Rockey DC, et al. Amoxicillin–Clavulanate-Induced liver injury. Dig Dis Sci. 2016;61(8):2406–2416.
   PubMed Web of Science ®Google Scholar
• Alqahtani SA, Kleiner DE, Ghabril M, et al. For the DILIN study investigators. Identification and characterization of cefazolin-induced liver injury. Clin Gastroenterol Hepatol. 2015;13(7):1328–1336.e2.
   PubMed Web of Science ®Google Scholar
• Polson JE. Hepatotoxicity due to antibiotics. Clin Liver Dis. 2007;11(3):549–561. vi.
   PubMedGoogle Scholar
• Andrade RJ, Tulkens PM. Hepatic safety of antibiotics used in primary care. J Antimicrob Chemother. 2011;66(7):1431–1446.
   PubMed Web of Science ®Google Scholar
• Stine JG, Lewis JH. Hepatotoxicity of antibiotics: a review and update for the clinician. Clin Liver Dis. 2013;17(4):609–642, ix.
   PubMed Web of Science ®Google Scholar
• Paterson MJ, Mamdani MM, Manno M, Juurlink DN. Fluoroquinolone therapy and idiosyncratic acute liver injury: a population-based study. CMAJ. 2012;184(14):1565–1570.
   PubMed Web of Science ®Google Scholar
• Alshammari TM, Larrat EP, Morrill HJ, et al. Risk of hepatotoxicity associated with fluoroquinolones: a national case-control safety study. Am J Health Syst Pharm. 2014;71(1):37–43.
   PubMed Web of Science ®Google Scholar
• Kaye JA, Castellsague J, Bui CL, et al. Risk of acute liver injury associated with the use of moxifloxacin and other oral antimicrobials: a retrospective, Population-Based cohort study. Pharmacotherapy. 2014;34(4):336–349.
   PubMedGoogle Scholar
• Björnsson E, Olsson R. Outcome and prognostic markers in severe drug-induced liver disease. Hepatology. 2005;42(2):481–489.
   PubMed Web of Science ®Google Scholar
• Chalasani N, Fontana RJ, Bonkovsky HL, et al. Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. Gastroenterology. 2008;135(6):1924–1934.
   PubMed Web of Science ®Google Scholar
• Chalasani N, Bonkovsky HL, Fontana R, et al. Features and outcomes of 899 patients with drug-Induced liver injury: the DILIN prospective study. Gastroenterology. 2015;148(7):1340–1352.e7.
   PubMed Web of Science ®Google Scholar
• Björnsson E, Jerlstad P, Bergqvist A, et al. Fulminant drug-induced hepatic failure leading to death or liver transplantation in Sweden. Scand J Gastroenterol. 2005;40(9):1095–1101.
   PubMed Web of Science ®Google Scholar
• Vindegaard N, Benros ME. COVID-19 pandemic and mental health consequences: Systematic review of the current evidence. Brain Behav Immun. 2020;89:531–542.
   PubMed Web of Science ®Google Scholar
• Hossain MM, Tasnim S, Sultana A, et al. Epidemiology of mental health problems in COVID-19: a review. F1000Res. 2020;9:636.
   PubMedGoogle Scholar
• Ostuzzi G, Papola D, Gastaldon C, et al. Safety of psychotropic medications in people with COVID-19: evidence review and practical recommendations. BMC Med. 2020;18(1):215.
   PubMed Web of Science ®Google Scholar
• Bilbul M, Paparone P, Kim AM, et al. Psychopharmacology of COVID-19. Psychosomatics. 2020;61(5):411–427.
   PubMed Web of Science ®Google Scholar
• Goldberg J, Ernst C. Managing the side effects of psychotropic medications. 2nd ed. Washington DC: American Psychiatric Association Publishing;2019. p.195–196.
   Google Scholar
• Telles-Correia D, Barbosa A, Cortez-Pinto H, et al. Psychotropic drugs and liver disease: a critical review of pharmacokinetics and liver toxicity. World J Gastrointest Pharmacol Ther. 2017;8(1):26–38.
   PubMedGoogle Scholar
• Bishara D, Kalafatis C, Taylor D. Emerging and experimental treatments for COVID-19 and drug interactions with psychotropic agents. Ther Adv Psychopharmacol. 2020;10:2045125320935306.
   Web of Science ®Google Scholar
• Barazzoni R, Bischoff SC, Breda J, et al. ESPEN expert statements and practical guidance for nutritional management of individuals with SARS-CoV-2 infection. Clin Nutr. 2020;39(6):1631–1638.
   PubMed Web of Science ®Google Scholar
• Li G, Zhou CL, Ba YM, et al. Nutritional risk and therapy for severe and critical COVID-19 patients: a multicenter retrospective observational study. Clin Nutr. 2021;40(4):2154–2161.
   PubMedGoogle Scholar
• Lew CCH, Yandell R, Fraser RJL, et al. Association between malnutrition and clinical outcomes in the intensive care unit: a systematic review [formula: see text]. JPEN J Parenter Enteral Nutr. 2017;41(5):744–758.
   PubMed Web of Science ®Google Scholar
• Ferrara F, Rosa Vitiello DF. A. The Central role of clinical nutrition in COVID-19 patients during and after hospitalization in intensive care unit. SN Compr Clin Med. 2020:1–5.
   Google Scholar
• Pironi L, Sasdelli AS, Ravaioli F, et al. Malnutrition and nutritional therapy in patients with SARS-CoV-2 disease. Clin Nutr. 2021;40(3):1330–1337.
   PubMedGoogle Scholar
• Quigley EM, Marsh MN, Shaffer JL, et al. Hepatobiliary complications of total parenteral nutrition. Gastroenterology. 1993;104(1):286–301.
   PubMed Web of Science ®Google Scholar
• Kumpf VJ, Gervasio J. Complications of parenteral nutrition. In: Mueller CM, editor. The ASPEN adult nutrition support core curriculum. Silver Spring, MD: American Society for Parenteral and Enteral Nutrition;2017. p. 345–360.
   Google Scholar
• Lakananurak N, Tienchai K. Incidence and risk factors of parenteral nutrition-associated liver disease in hospitalized adults: a prospective cohort study. Clin Nutr ESPEN. 2019;34:81–86.
   PubMedGoogle Scholar
• Mitra A, Ahn J. Liver disease in patients on total parenteral nutrition. Clin Liver Dis. 2017;21(4):687–695.
   PubMedGoogle Scholar
• Madnawat H, Welu AL, Gilbert EJ, et al. Mechanisms of parenteral Nutrition-Associated liver and gut injury. Nutr Clin Pract. 2020;35(1):63–71.
   PubMed Web of Science ®Google Scholar
• Rodriguez-Morales AJ, Cardona-Ospina JA, Gutiérrez-Ocampo E, et al. Clinical, laboratory and imaging features of COVID-19: a systematic review and Meta-analysis. Travel Med Infect Dis. 2020;34:101623. https://www.lancovid.org.
   PubMed Web of Science ®Google Scholar
• Bertolino L, Vitrone M, Durante-Mangoni E. Does this patient have COVID-19? A practical guide for the internist. Intern Emerg Med. 2020;15(5):791–800.
   PubMedGoogle Scholar
• World Health Organization. 2020. Clinical management of COVID-19: interim guidance, 27 May 2020. World Health Organization. Available from: https://www.who.int/publications/i/item/clinical-management-of-covid-19.
   Google Scholar
• Larson AM. Acetaminophen hepatotoxicity. Clin Liver Dis. 2007;11(3):525–548, vi.
   PubMedGoogle Scholar
• Chun LJ, Tong MJ, Busuttil RW, et al. Acetaminophen hepatotoxicity and acute liver failure. J Clin Gastroenterol. 2009;43(4):342–349.
   PubMed Web of Science ®Google Scholar
• Yoon E, Babar A, Choudhary M, et al. Acetaminophen-Induced hepatotoxicity: a comprehensive update. J Clin Transl Hepatol. 2016;4(2):131–142.
   PubMed Web of Science ®Google Scholar
• Court MH, Duan SX, von Moltke LL, et al. Interindividual variability in acetaminophen glucuronidation by human liver microsomes: identification of relevant acetaminophen UDP-glucuronosyltransferase isoforms. J Pharmacol Exp Ther. 2001;299(3):998–1006.
   PubMed Web of Science ®Google Scholar
• Maruo Y, Nakahara S, Yanagi T, et al. Genotype of UGT1A1 and phenotype correlation between Crigler-Najjar syndrome type II and gilbert syndrome. J Gastroenterol Hepatol. 2016;31(2):403–408.
   PubMedGoogle Scholar
• Britza SM, Musgrave IF, Byard RW. Paracetamol (acetaminophen) hepatotoxicity increases in the presence of an added herbal compound. Leg Med (Tokyo). 2020;47:101740.
   PubMed Web of Science ®Google Scholar
• Sestili P, Fimognari C. Paracetamol-Induced glutathione consumption: is there a link with severe COVID-19 illness? Front Pharmacol. 2020;11:579944.
   PubMedGoogle Scholar
• Aydemir D, Ulusu NN. Is glucose-6-phosphate dehydrogenase enzyme deficiency a factor in coronavirus-19 (COVID-19) infections and deaths? Pathog Glob Health. 2020;114(3):109–110.
   PubMed Web of Science ®Google Scholar
• Polonikov A. Endogenous deficiency of glutathione as the most likely cause of serious manifestations and death in COVID-19 patients. ACS Infect Dis. 2020;6(7):1558–1562.
   PubMed Web of Science ®Google Scholar
• Saadat M. An evidence for correlation between the glutathione S-transferase T1 (GSTT1) polymorphism and outcome of COVID-19. Clin Chim Acta. 2020;508:213–216.
   PubMedGoogle Scholar
• Leventhal TM, Gottfried M, Olson JC, et al. Acetaminophen is undetectable in plasma from more than half of patients believed to have acute liver failure due to overdose. Clin Gastroenterol Hepatol. 2019;17(10):2110–2116.
   PubMed Web of Science ®Google Scholar
• Klok FA, Kruip MJHA, van der Meer NJM, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res. 2020;191:145–147.
   PubMed Web of Science ®Google Scholar
• Biere-Rafi S, Hutten BA, Squizzato A, et al. Statin treatment and the risk of recurrent pulmonary embolism. Eur Heart J. 2013;34(24):1800–1806.
   PubMed Web of Science ®Google Scholar
• Glynn RJ, Danielson E, Fonseca FA, et al. A randomized trial of rosuvastatin in the prevention of venous thromboembolism. N Engl J Med. 2009;360(18):1851–1861.
   PubMed Web of Science ®Google Scholar
• Lee KCH, Sewa DW, Phua GC. Potential role of statins in COVID-19. Int J Infect Dis. 2020;96:615–617.
   PubMedGoogle Scholar
• Zhang XJ, Qin JJ, Cheng X, et al. In-Hospital use of statins is associated with a reduced risk of mortality among individuals with COVID-19. Cell Metab. 2020;32(2):176–187.e4.
   PubMed Web of Science ®Google Scholar
• Lopes RD, Macedo AVS, de Barros E, et al. Effect of discontinuing vs continuing Angiotensin-Converting enzyme inhibitors and angiotensin II receptor blockers on days alive and out of the hospital in patients admitted with COVID-19: a randomized clinical trial. JAMA. 2021;325(3):254–264.
   PubMed Web of Science ®Google Scholar
• Patti G, Lio V, Cavallari I, et al. Antithrombotic treatments in patients with SARS-CoV-2 infection: from current evidence to reasonable recommendations - A position paper from the italian working group on atherosclerosis, thrombosis and vascular biology. G Ital Cardiol (Rome). 2020;21(7):489–501.
   PubMedGoogle Scholar
• Carlson MK, Gleason PP, Sen S. Elevation of hepatic transaminases after enoxaparin use: case report and review of unfractionated and low-molecular-weight heparin-induced hepatotoxicity. Pharmacotherapy. 2001;21(1):108–113.
   PubMedGoogle Scholar
• Richardson P, Griffin I, Tucker C, et al. Baricitinib as potential treatment for 2019-nCoV acute respiratory disease. Lancet. 2020;395(10223):e30–e31.
   PubMed Web of Science ®Google Scholar
• Stebbing J, Krishnan V, de Bono S, et al. Mechanism of baricitinib supports artificial intelligence-predicted testing in COVID-19 patients. EMBO Mol Med. 2020;12(8):e12697.
   PubMed Web of Science ®Google Scholar
• Titanji BK, Farley MM, Mehta A, Connor-Schuler R, et al. Use of baricitinib in patients with moderate and severe COVID-19. Clin Infect Dis. 2021;72(7):1247–1250.
   PubMedGoogle Scholar
• Cantini F, Niccoli L, Matarrese D, et al. Baricitinib therapy in COVID-19: a pilot study on safety and clinical impact. J Infect. 2020;81(2):318–356.
   PubMed Web of Science ®Google Scholar
• LiverTox: Clinical and research information on Drug-Induced liver injury. [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012. Baricitinib. [Last Update 2020 Dec 2]. https://pubmed.ncbi.nlm.nih.gov/31643176/
   Google Scholar
• Kalil AC, Patterson TF, Mehta AK, et al. ACCT-2 study group members. Baricitinib plus remdesivir for hospitalized adults with covid-19. N Engl J Med. 2021;384(9):795–807.
   PubMed Web of Science ®Google Scholar
• Leegwater E, Strik A, Wilms EB, et al. Drug-induced liver injury in a patient with coronavirus disease 2019: Potential interaction of remdesivir with P-Glycoprotein inhibitors. Clin Infect Dis. 2021;72(7):1256–1258.
   PubMed Web of Science ®Google Scholar